Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Falk

Showing results (511-520 of 537) with videos related to

Pageof 54
Sort By:
JACC. Cardiovascular Imaging|September 12, 2025
Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell TherapyDominik C Benz, Olivier F Clerc, Sarah A M Cuddy, et al.
The American Journal of Cardiology|August 14, 2003
Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T])Steven N Singh, Bramah N Singh, Domenic J Reda, et al.
Journal of Neural Engineering|August 9, 2019
Brain-computer interfaces and personhood: interdisciplinary deliberations on neural technologyMatthew Sample, Marjorie Aunos, Stefanie Blain-Moraes, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 7, 2019
Quantitative [<sup>18</sup>F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosisYiu Ming Khor, Sarah Cuddy, Hendrik J Harms, et al.
JACC. Cardiovascular Imaging|July 13, 2024
Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain AmyloidosisOlivier F Clerc, Sarah A M Cuddy, Michael Jerosch-Herold, et al.
Medrxiv : the Preprint Server for Health Sciences|October 24, 2023
Myocardial Characterization for Early Diagnosis, Treatment Response Monitoring, and Risk Assessment in Systemic Light-Chain AmyloidosisOlivier F Clerc, Sarah A M Cuddy, Michael Jerosch-Herold, et al.
Journal of the American College of Cardiology|March 20, 2019
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyDaniel P Judge, Stephen B Heitner, Rodney H Falk, et al.
Frontiers in Cardiovascular Medicine|June 14, 2024
Mechanisms of left ventricular systolic dysfunction in light chain amyloidosis: a multiparametric cardiac MRI studyEthan Katznelson, Michael Jerosch-Herold, Sarah A M Cuddy, et al.
Basic Research in Cardiology|August 29, 2013
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicityJian Guan, Shikha Mishra, Jianru Shi, et al.
JACC. Cardiovascular Imaging|May 18, 2020
Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease?Sarah A M Cuddy, Paco E Bravo, Rodney H Falk, et al.
Pageof 54

Showing results (511-520 of 537) with videos related to

Sort By:
Pageof 54
JACC. Cardiovascular Imaging|September 12, 2025
Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell TherapyDominik C Benz, Olivier F Clerc, Sarah A M Cuddy, et al.
The American Journal of Cardiology|August 14, 2003
Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T])Steven N Singh, Bramah N Singh, Domenic J Reda, et al.
Journal of Neural Engineering|August 9, 2019
Brain-computer interfaces and personhood: interdisciplinary deliberations on neural technologyMatthew Sample, Marjorie Aunos, Stefanie Blain-Moraes, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 7, 2019
Quantitative [<sup>18</sup>F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosisYiu Ming Khor, Sarah Cuddy, Hendrik J Harms, et al.
JACC. Cardiovascular Imaging|July 13, 2024
Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain AmyloidosisOlivier F Clerc, Sarah A M Cuddy, Michael Jerosch-Herold, et al.
Medrxiv : the Preprint Server for Health Sciences|October 24, 2023
Myocardial Characterization for Early Diagnosis, Treatment Response Monitoring, and Risk Assessment in Systemic Light-Chain AmyloidosisOlivier F Clerc, Sarah A M Cuddy, Michael Jerosch-Herold, et al.
Journal of the American College of Cardiology|March 20, 2019
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid CardiomyopathyDaniel P Judge, Stephen B Heitner, Rodney H Falk, et al.
Frontiers in Cardiovascular Medicine|June 14, 2024
Mechanisms of left ventricular systolic dysfunction in light chain amyloidosis: a multiparametric cardiac MRI studyEthan Katznelson, Michael Jerosch-Herold, Sarah A M Cuddy, et al.
Basic Research in Cardiology|August 29, 2013
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicityJian Guan, Shikha Mishra, Jianru Shi, et al.
JACC. Cardiovascular Imaging|May 18, 2020
Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease?Sarah A M Cuddy, Paco E Bravo, Rodney H Falk, et al.
Pageof 54